Glaukos Corporation has entered into a definitive Agreement and Plan of Merge to acquire Dose Medical Corporation, a developer of microinvasive, bioerodible, sustained-release drug delivery platforms for various retinal diseases.
The acquisition will cost Glaukos $2.5 million in cash plus performance-based consideration upon achievement of certain regulatory approvals and commercial milestones, according to a company press release.
The transaction, which is expected to close in this quarter and which includes all remaining assets and liabilities of Dose Medical, will make the company a wholly
Uncategorized